CuraGen
Founded Year
1991Stage
Acq - P2P | AcquiredTotal Raised
$39.29MValuation
$0000Missing: CuraGen's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: CuraGen's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing CuraGen
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
CuraGen is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
CuraGen Patents
CuraGen has filed 4 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/26/2014 | 5/14/2019 | Glucocorticoids, Oncology, Antineoplastic drugs, Experimental cancer drugs, Cancer treatments | Grant |
Application Date | 11/26/2014 |
|---|---|
Grant Date | 5/14/2019 |
Title | |
Related Topics | Glucocorticoids, Oncology, Antineoplastic drugs, Experimental cancer drugs, Cancer treatments |
Status | Grant |
Latest CuraGen News
Jul 13, 2021
BOULDER — Clovis Oncology (NYSE: CLVS) is increasing the number of directors on its board from 10 to 11 and filling that vacancy with Dr. Ronit Simantov, the company announced Monday in a news release. Simantov is the chief medical officer at the cell-therapy company Gamida Cell Ltd. She had previously served as vice president for oncology global medical affairs at Pfizer Inc, with other experience at OSI Pharmaceuticals, CuraGen Corporation and Bayer HealthCare Pharmaceuticals. Simantov will receive $55,000 in annual cash retainers for her role on the board. She will also receive a one-time option to purchase 83,212 shares of Clovis Oncology stock. © 2021 BizWest Media LLC BOULDER — Clovis Oncology (NYSE: CLVS) is increasing the number of directors on its board from 10 to 11 and filling that vacancy with Dr. Ronit Simantov, the company announced Monday in a news release. Simantov is the chief medical officer at the cell-therapy company Gamida Cell Ltd. She had previously served as vice president for oncology global medical affairs at Pfizer Inc, with other experience at OSI Pharmaceuticals, CuraGen Corporation and Bayer HealthCare Pharmaceuticals. Simantov will receive $55,000 in annual cash retainers for her role on the board. She will also receive a one-time option to purchase 83,212 shares of Clovis Oncology stock. © 2021 BizWest Media LLC
CuraGen Frequently Asked Questions (FAQ)
When was CuraGen founded?
CuraGen was founded in 1991.
Where is CuraGen's headquarters?
CuraGen's headquarters is located at 322 East Main Street, Branford.
What is CuraGen's latest funding round?
CuraGen's latest funding round is Acq - P2P.
How much did CuraGen raise?
CuraGen raised a total of $39.29M.
Who are the investors of CuraGen?
Investors of CuraGen include Celldex Therapeutics, Cooper Hill Partners, Soros Fund Management and Pequot Venture Capital.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.